The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy

[11] Xu H(2022)BRCA mutation status in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: a pivotal role for treatment decision-making Cancers 14 4571-160

[12] Kou D(2015)Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance) J Clin Oncol 33 13-1463

[13] Li R(2021)Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness NPJ Breast Cancer 7 142-313

[14] Li M(2018)Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort Breast 40 141-5618

[15] Mittal A(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [published correction appears in Lancet. 2019 Mar 9;393(10175):986] Lancet 384 164-566

[16] Deo SV(2022)Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients Lancet Oncol 23 149-7038

[17] Gogia A(2020)Presymptomatic awareness of germline pathogenic BRCA variants and associated outcomes in women with breast cancer JAMA Oncol 6 1460-76

[18] Batra A(2016)Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice Blood 127 310-1452

[19] Kumar A(2019)Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: a retrospective matched cohort study Cancer Med 8 5609-821

[20] Bhoriwal S(2016)Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer Breast Cancer Res Treat 156 557-142

[11] Xu H(2022)BRCA mutation status in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: a pivotal role for treatment decision-making Cancers 14 4571-160

[12] Kou D(2015)Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance) J Clin Oncol 33 13-1463

[13] Li R(2021)Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness NPJ Breast Cancer 7 142-313

[14] Li M(2018)Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort Breast 40 141-5618

[15] Mittal A(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [published correction appears in Lancet. 2019 Mar 9;393(10175):986] Lancet 384 164-566

[16] Deo SV(2022)Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients Lancet Oncol 23 149-7038

[17] Gogia A(2020)Presymptomatic awareness of germline pathogenic BRCA variants and associated outcomes in women with breast cancer JAMA Oncol 6 1460-76

[18] Batra A(2016)Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice Blood 127 310-1452

[19] Kumar A(2019)Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: a retrospective matched cohort study Cancer Med 8 5609-821

[20] Bhoriwal S(2016)Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer Breast Cancer Res Treat 156 557-142